Device maker MAX Endoscopy Inc. and drug developer TheraVasc Inc. each have received $250,000 follow-on investments from JumpStart Ventures, the investment arm of Northeast Ohio venture developer JumpStart Inc.
The new commitments follow initial investments of the same amount that JumpStart made in the two companies last winter.
Macedonia-based MAX Endoscopy designs and makes a fiber-optic device used in treating hemorrhoids. A burst of infrared light delivered by the device causes blood in the hemorrhoids to harden, so the hemorrhoids shrink. MAX Endoscopy’s device received federal regulatory approval last year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company will use the latest round of funding to speed up the commercialization process, expand its management team, and begin evaluating other clinical opportunities, such as Barrett’s Esophagus and watermelon stomach, according to a statement from JumpStart.
Cleveland-based TheraVasc is reformulating an approved drug to treat vascular diseases. The funding from JumpStart will be used to support a Phase 2a clinical trial to determine the effectiveness of the company’s sodium nitrate drug. The study will try to find out whether the drug improves blood flow for sufferers of peripheral arterial disease, a narrowing of the blood vessels in the extremities, usually the legs.
Sodium nitrate already is approved by the Food and Drug Administration as an injectable. TheraVasc is working to reformulate it as a capsule. In addition to receiving a commitment of $250,000 from JumpStart in January, TheraVasc received the same amount of investment from Portal Capital LLC, an early stage life sciences investment firm in Beachwood.
